THIO Plus Cemiplimab Associated with Prolonged OS in ICI-Resistant NSCLC

MAIA Biotechnology (MAIA) - THIO Update Shows Another Increase In Overall Survival - Channelchek

Friday, June 06, 2025 MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive canc…

THIO Plus Cemiplimab Associated with Prolonged OS in ICI-Resistant NSCLC

THIO with cemiplimab is active and well-tolerated in patients with advanced non–small cell lung cancer resistant to immune checkpoint inhibitors in second- and third-line settings.

THIO/Cemiplimab Combo Shows Activity in ICI-Resistant NSCLC

A novel combination therapy shows promise for advanced lung cancer patients resistant to standard treatments, offering hope for improved survival rates.